IRMA-International.org: Creator of Knowledge
Information Resources Management Association
Advancing the Concepts & Practices of Information Resources Management in Modern Organizations

Ligand- and Structure-Based Drug Design of Non-Steroidal Aromatase Inhibitors (NSAIs) in Breast Cancer

Ligand- and Structure-Based Drug Design of Non-Steroidal Aromatase Inhibitors (NSAIs) in Breast Cancer
View Sample PDF
Author(s): Tarun Jha (Jadavpur University, India), Nilanajn Adhikari (Jadavpur University, India), Amit Kumar Halder (Jadavpur University, India)and Achintya Saha (University of Calcutta, India)
Copyright: 2017
Pages: 69
Source title: Oncology: Breakthroughs in Research and Practice
Source Author(s)/Editor(s): Information Resources Management Association (USA)
DOI: 10.4018/978-1-5225-0549-5.ch004

Purchase

View Ligand- and Structure-Based Drug Design of Non-Steroidal Aromatase Inhibitors (NSAIs) in Breast Cancer on the publisher's website for pricing and purchasing information.

Abstract

Aromatase is a multienzyme complex overexpressed in breast cancer and responsible for estrogen production. It is the potential target for designing anti-breast cancer drugs. Ligand and Structure-Based Drug Designing approaches (LBDD and SBDD) are involved in development of active and more specific Nonsteroidal Aromatase Inhibitors (NSAIs). Different LBDD and SBDD approaches are presented here to understand their utility in designing novel NSAIs. It is observed that molecules should possess a five or six membered heterocyclic nitrogen containing ring to coordinate with heme portion of aromatase for inhibition. Moreover, one or two hydrogen bond acceptor features, hydrophobicity, and steric factors may play crucial roles for anti-aromatase activity. Electrostatic, van der Waals, and p-p interactions are other important factors that determine binding affinity of inhibitors. HQSAR, LDA-QSAR, GQSAR, CoMFA, and CoMSIA approaches, pharmacophore mapping followed by virtual screening, docking, and dynamic simulation may be effective approaches for designing new potent anti-aromatase molecules.

Related Content

Genevieve Z. Steiner-Lim, Madilyn Coles, Kayla Jaye, Najwa-Joelle Metri, Ali S. Butt, Katerina Christofides, Jackson McPartland, Zainab Al-Modhefer, Diana Karamacoska, Ethan Russo, Tim Karl. © 2023. 47 pages.
Mohd Kashif, Mohammad Waseem, Poornima D. Vijendra, Ashok Kumar Pandurangan. © 2023. 28 pages.
Courtney R. Acker, Rana R. Zeine. © 2023. 27 pages.
Mahesh Pattabhiramaiah, Shanthala Mallikarjunaiah. © 2023. 16 pages.
Dhairavi Shah, Dhaara Shah, Yara Mohamed, Danna Rosas, Alyssa Moffitt, Theresa Hearn Haynes, Francis Cortes, Taunjah Bell Neasman, Phani kumar Kathari, Ana Villagran, Rana R. Zeine. © 2023. 28 pages.
Mohammad Uzair, Hammad Qaiser, Muhammad Arshad, Aneesa Zafar, Shahid Bashir. © 2023. 23 pages.
Akila Muthuramalingam, Ashok Kumar Pandurangan, Subhamoy Banerjee. © 2023. 17 pages.
Body Bottom